Page 3
Icosavax lands on $182m IPO
UW's vaccine development company has listed on Nasdaq, with its shares rising on the first day of trading.
Tenaya tends to $180m IPO
The GV-backed cardiovascular therapeutics company has priced an upsized offering on Nasdaq, with the shares closing just marginally higher on the first day.
IN8Bio initiates $40m IPO
IN8Bio, a University of Alabama spinout and cancer immunotherapy developer, has pulled in $40m through its IPO.
Duolingo brings in $521m IPO
Carnegie Mellon-linked Duolingo raised $521m in an upsized offering and saw its shares rise 36% on their first day.
Sema4 secures Nasdaq listing
Icahn School of Medicine spinout Sema4 has completed a reverse merger with CM Life Sciences to begin trading on the Nasdaq Global Select Market.
Sophia Genetics secures $234m in IPO
Genomics analytics platform developer Sophia Genetics has gone public ten years after it was co-founded by researchers from EMBL, Stanford and University of Geneva
Caribou Biosciences careers on to public markets
UC Berkeley’s cancer therapy developer priced a $304m initial public offering at the top of its range.
IsoPlexis applies itself to IPO filing
Yale University is in line to exit proteomics platform developer IsoPlexis in a Nasdaq Global Market offering with a $100m placeholder target.
Kin to clinch public markets spot
The UChicago-backed digital home insurance provider is joining forces with Omnichannel Acquisition Corp at a valuation of just over $1bn.
TScan takes in $100m through IPO
Harvard spinout TScan Therapeutics has successfully listed on the Nasdaq Global Market.